Skip to main content

Polyphor discovers new class of antibiotics

| News

Polyphor discovers new class of antibiotics


Researchers at the Allschwil pharmaceutical company Polyphor and the University of Zurich have discovered a novel antibiotics class. It has a unique mechanism of action that allows it to target multiple bacteria.

Research (Img: Alex011973/shutterstock)

The rapid emergence of antimicrobial resistance is a huge problem, particularly Gram-negative bacteria, according to a statement from the University of Zurich (UZH). Working with colleagues at Polyphor, UZH researchers have now discovered a new class of antibiotics that is effective against several Gram-negative microbes. In its own statement, Polyphor writes that the University of Basel, its Biozentrum and the Federal Institute of Technology in Zurich (ETH) were also involved in the research. The study was published in “Nature”.

The new class is known as Outer Membrane Protein Targeting Antibiotics (OMPTA). “The new antibiotics interact with essential outer membrane proteins in Gram-negative bacteria,” commented John Robinson from the UZH Department of Chemistry, who co-headed the study, in the UZH statement. The outer membrane of Gram-negative bacteria is important, because it protects the cells from toxic environmental factors such as antibiotics and is responsible for the uptake of nutrients. The antibiotics bind to complex fat-like substances “and to BamA, an essential protein of the outer membrane of Gram-negative bacteria”, explained Robinson. When the novel antibiotics bind to BamA, they destroy the membranes and the cells burst. Currently no clinical antibiotics target the outer membrane proteins, making the Polyphor and UZH finding particularly novel.

Polyphor is set to conduct in-human clinical trials on the new class of antibiotics. “POL7306, a first lead molecule of the OMPTA class, is now in preclinical development,” said Daniel Obrecht, chief scientific officer at Polyphor and co-head of the work. In the Polyphor statement he added: “We are proud to have discovered a novel class of antibiotics potentially addressing a major unmet medical need.” He also acknowledged the financial support of Innosuisse – the federal innovation agency, the Wellcome Trust, the Novo REPAIRImpact Fund and CARB-X.

CARB-X is one of the world’s biggest public-private partnerships conducting groundbreaking research to combat drug-resistant bacteria. Representing the Basel region, which is a leading center for antibiotics research, is a member of CARB-X. The location promotion organization supports businesses eligible for CARB-X funding and consults the network regarding the support of companies.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.